tiprankstipranks
Advertisement
Advertisement

GHRS Stock Latest News

Analyst Reiterates Buy on GH Research as GH001 Advances Toward Phase 3; $65 Price Target Maintained
RatingsAnalyst Reiterates Buy on GH Research as GH001 Advances Toward Phase 3; $65 Price Target Maintained
15d ago
GHRS
GH Research price target raised to $40 from $35 at Cantor Fitzgerald
PremiumThe Fly
GH Research price target raised to $40 from $35 at Cantor Fitzgerald
18d ago
GHRS
GH Research price target raised to $40 from $34 at Guggenheim
PremiumThe Fly
GH Research price target raised to $40 from $34 at Guggenheim
18d ago
GHRS
GH Research Earns Buy Rating on FDA Phase 3 Green Light, Strong TRD Strategy and Solid Cash Runway
PremiumRatings
GH Research Earns Buy Rating on FDA Phase 3 Green Light, Strong TRD Strategy and Solid Cash Runway
18d ago
GHRS
GH Research price target raised to $39 from $32 at Needham
PremiumThe Fly
GH Research price target raised to $39 from $32 at Needham
19d ago
GHRS
Psychedelic: Compass Pathways, GH Research report quarterly earnings
PremiumThe FlyPsychedelic: Compass Pathways, GH Research report quarterly earnings
19d ago
CMND
CMPS
GH Research reports Q2 EPS (23c), consensus (30c)
Premium
The Fly
GH Research reports Q2 EPS (23c), consensus (30c)
19d ago
GHRS
GH Research Files Q2 2026 Results and Updates Corporate Presentation
Premium
Company Announcements
GH Research Files Q2 2026 Results and Updates Corporate Presentation
19d ago
6K
GHRS
Psychedelic: Clearmind reports safety findings for CMND-100
PremiumThe Fly
Psychedelic: Clearmind reports safety findings for CMND-100
26d ago
CMND
CMPS
GH Research initiated with an Overweight at Wells Fargo
PremiumThe Fly
GH Research initiated with an Overweight at Wells Fargo
29d ago
GHRS
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
PremiumThe Fly
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
1M ago
LLY
ATAI
Helus Pharma price target lowered to $45 from $48 at Guggenheim
PremiumThe Fly
Helus Pharma price target lowered to $45 from $48 at Guggenheim
1M ago
LLY
ATAI
AtaiBeckley downgraded to Hold from Buy at JonesResearch
PremiumThe FlyAtaiBeckley downgraded to Hold from Buy at JonesResearch
1M ago
ATAI
CMPS
FDA announces availability of final guidance for psychedelic drug research
Premium
The Fly
FDA announces availability of final guidance for psychedelic drug research
1M ago
ATAI
CMND
VA, HHS sign MOU to improve cooperation on psychedelic drug trials
Premium
The Fly
VA, HHS sign MOU to improve cooperation on psychedelic drug trials
1M ago
ATAI
CMPS
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
PremiumThe Fly
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
1M ago
ATAI
CMPS
GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM
PremiumCompany Announcements
GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM
2M ago
6K
GHRS
Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003
PremiumThe Fly
Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003
3M ago
CMND
ENVB
GH Research announces publication of Phase 2a results for mebufotenin
PremiumThe Fly
GH Research announces publication of Phase 2a results for mebufotenin
3M ago
GHRS
GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001
PremiumCompany AnnouncementsGH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001
3M ago
6K
GHRS
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
Premium
The Fly
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
3M ago
CMND
CMPS
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026
Premium
Company Announcements
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026
3M ago
6K
GHRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >